JAK2 V617F mutation analysis

JAK2 p.Val617Phe (c.1849G>T) mutation analysis
Lab Test name Contact Comments
AZ St-Jan Brugge - Laboratoriumgeneeskunde JAK2 V617F mutation analysis dr. Helena Devos/Friedel Nollet, Ph.D.
LNA based real time PCR with WT-JAK2 blocking probe
based on Denys et al., Journal of Molecular Diagnostics (2010)
DNA-test
Version date: 04/11/2017
Accredited:
UZA Mol. Diagn. JAK2 V617F mutation analysis K. Vermeulen, M-B Maes
IPG Gosselies JAK2 V617F mutation analysis
UZ Gent JAK2 V617F mutation analysis Barbara Denys
Karl Vandepoele
JAK2 c.1849G>T; p.Val617Phe
Real-time PCR with LNA WT-JAK2 blocking probe
Denys et al., J Mol Diagn 2010
DNA-test
Version date: 31/05/2017
Accredited:
UZ Brussel - Molecular Hematology JAK2 V617F mutation analysis Marleen Bakkus/Christian Demanet
c.1849G>T; p.Val617Phe
Real-time PCR with LNA WT-JAK2 blocking probe
Sensitivity: <0.1%
Denys et al., J Mol Diagn 2010
DNA-test
Version date: 26/09/2017
Accredited:
CHU Liège - Hemato JAK2 V617F mutation analysis Dr Frédéric Lambert
As described by Sidon P et al., Clin Chem, 2006 and Denys B et al., J Mol Diagn. 2010
Jessa Hospital JAK2 V617F mutation analysis Dr. Brigitte Maes, Femke Hillen
SAMPLE TYPE:
Blood or bone marrow (1ml, EDTA)
TRANSPORT: room temperature, within 24h after sampling
FREQUENCY: 1x/week
TEST TYPE: Real-time RT-PCR, allelic discrimination, in house method
CUB Erasme - Medical Genetics Dpt JAK2 V617F mutation analysis Pierre Heimann/Barbara Dessars/Hakim El Housni
Real-time PCR with LNA WT-JAK2 blocking probe
based on Sidon et al., Clin Chem (2006) with modifications
DNA-test
GZA St-Augustinus JAK2 V617F mutation analysis Philippe Van Lint
real time PCR with LNA WT-JAK2 blocking probe
based on Sidon et al., Clin Chem (2006) with modifications
DNA-test

performed on whole blood, or bone marrow (EDTA)

frequency: 1x/week
Accredited:
OLVZ Aalst JAK2 V617F mutation analysis Freya Vaeyens
Sample type:
EDTA-Blood or bone marrow (500 µl)

Frequency: Daily (except weekend)

Test type: In house real time PCR
Version date: 29/09/2017
Accredited:
AZ St-Lucas Gent JAK2 V617F mutation analysis Dr H. Louagie / Koen Jacobs
SAMPLE TYPE: Blood or bone marrow

FREQUENCY: 1x/2weeks

TEST TYPE: JAK2 V617F mutaquant kit (Ipsogen)
AZ Delta JAK2 V617F mutation analysis Elisabeth Moreau/Elke Boone
SAMPLE TYPE: Blood or bone marrow (1ml, EDTA)
FREQUENCY: 1x/2-weeks
TEST TYPE: RT-PCR followed by RFLP, in house method
Version date: 05/12/2017
Accredited:
ZNA Middelheim JAK2 V617F mutation analysis Pieter De Schouwer
Sample type: bone marrow or EDTA blood
Frequency: once a week
test type: in house PCR
Labo Cliniques Sud Luxembourg JAK2 V617F mutation analysis Nicolas Hougardy
SAMPLE TYPE:
- Blood (EDTA) (min 200µL)
- Bone Marrow (EDTA) (min 2,5ml)
FREQUENCY: every two weeks
TEST TYPE : In-House, Real time PCR (Screening of acquired abnormalities in the diagnosis of a CML and for the follow-up of a myeloid affection), LightCycler 2.0 (Roche)
ARTICLES: "Lay Jmol Diag, 2006, 8, n°3, 330-334" and "Mac Clure leukemia, 2006,168-171"
UZ Leuven MolPLUZ JAK2 V617F mutation analysis Lucienne Michaux / Els Lierman
Sample type: blood / bone marrow (EDTA, 2-5 ml)
Frequency: 1x/week
Test type: digital droplet PCR (ddPCR) on DNA with PrimePCR ddPCR Mutation Assay (Bio-Rad) for the p.V617F mutation in JAK2.
Accredited:
AZ Damiaan Oostende JAK2 V617F mutation analysis Ben Vanmassenhove/ Anne-Sophie Hervent
Protocol: B. Denys et al (2010)
Accredited: